Table 1 Patient demographics and baseline clinical characteristics (safety population)
Demographics | No | Eltrombopag | Eltrombopag | Eltrombopag | Total |
|---|---|---|---|---|---|
Eltrombopag | 75 mg | 100 mg | 150 mg | (N = 15) | |
(n = 3)a | (n = 7) | (n = 4) | (n = 1) | ||
Median age, y (range) | 56.0 (20–65) | 48.0 (38–62) | 30.5 (23–44) | 59.0 | 44.0 (20–65) |
Gender, n (%) | |||||
Female | 1 (33) | 4 (57) | 2 (50) | 1 (100) | 8 (53) |
Male | 2 (67) | 3 (43) | 2 (50) | 0 (0) | 7 (47) |
Race, n (%) | |||||
Hispanic or Latino | 1 (33) | 0 (0) | 2 (50) | 0 (0) | 3 (20) |
Not Hispanic or Latino | 2 (67) | 7 (100) | 2 (50) | 1 (100) | 12 (80) |
Baseline clinical characteristics | |||||
Median baseline platelet count, 1000/μL (range) | 256.0 | 300.0 | 264.0 | 388.0 | 281.0 |
(218–371) | (197–368) | (180–595) | (180–595) | ||
ECOG PS | |||||
ECOG 0, n (%) | 0 (0) | 6 (86) | 0 (0) | 1 (100) | 7 (47) |
ECOG 1, n (%) | 3 (100) | 1 (14) | 4 (100) | 0 (0) | 8 (53) |